HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer - Concepedia

Concepedia

Publication | Open Access

HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer

DOI Full Paper Access

14

Citations

31

References

2021

Year

Sarrah L. Hasanali, Daley S. Morera, Ronny R. Racine, Martin Hennig, Santu Ghosh, Luis E. López, Marie C. Hupe, Diogo O. Escudero, Jiaojiao Wang, Huabin Zhu,

Clinical Cancer Research

Abstract

V1/Chase drives gemcitabine resistance and potentially predicts gemcitabine + cisplatin failure. CDA inhibition resensitizes V1-expressing tumors to gemcitabine. Because several chemotherapy regimens include gemcitabine, our study could have broad significance.

References

	Year	Citations

Page 1